TCGA-CN-6992-01A-11R-1915-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- FATTY_ACID_METABOLISM+0.240
- OXIDATIVE_PHOSPHORYLATION+0.230
- WNT_BETA_CATENIN_SIGNALING+0.160
- MYC_TARGETS_V2+0.130
- MITOTIC_SPINDLE+0.090
- MTORC1_SIGNALING+0.090
- PANCREAS_BETA_CELLS+0.090
- BILE_ACID_METABOLISM+0.070
- UNFOLDED_PROTEIN_RESPONSE+0.060
- ADIPOGENESIS+0.050
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.650
- INTERFERON_GAMMA_RESPONSE-0.550
- TNFA_SIGNALING_VIA_NFKB-0.550
- IL6_JAK_STAT3_SIGNALING-0.480
- ALLOGRAFT_REJECTION-0.440
- INFLAMMATORY_RESPONSE-0.420
- COMPLEMENT-0.370
- ANGIOGENESIS-0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- TGF_BETA_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-AA6P-01A-11R-A39I-07 | — | — | 0.891 |
| 2 | TCGA-G2-AA3F-01A-12R-A42T-07 | — | — | 0.853 |
| 3 | SRR1442356 | GTEX | — | 0.839 |
| 4 | TCGA-DK-AA76-01A-11R-A39I-07 | — | — | 0.839 |
| 5 | TCGA-GV-A3JW-01A-11R-A20F-07 | — | — | 0.839 |
| 6 | 8fba9293-e3f1-41ef-b79e-499a02826174 | — | — | 0.836 |
| 7 | 84ca3236-683a-40f6-b8a6-600ffd43a0da | — | — | 0.833 |
| 8 | 37e6146e-6fec-4160-822c-404a517610a8 | — | — | 0.830 |
| 9 | SRR1072504 | GTEX | — | 0.830 |
| 10 | SRR5088850 | — | — | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.130 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.060 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.010 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.010 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |